Format

Send to

Choose Destination
Cancer Chemother Pharmacol. 2008 May;61(6):903-9. doi: 10.1007/s00280-008-0711-0. Epub 2008 Mar 4.

Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care.

Author information

1
ICAR, Department of Nephrology, Hôpital Pitié-Salpêtrière, 83 boulevard de l'Hôpital, 75013 Paris, France. vincent.launay-vacher@psl.aphp.fr

Abstract

Antineoplastic drugs used in the treatment of cancers present with variable renal tolerance profiles. Among drugs with a potential for renal toxicity, platinum salts, and especially cisplatin is a well-known agent that may induce acute and chronic renal failure. The mechanisms of its renal toxicity and the means of its prevention are presented in this article which represent the Clinical Recommendation from the Special Interest Group on Cancer Care of the European Society of Clinical Pharmacy (ESCP).

PMID:
18317762
DOI:
10.1007/s00280-008-0711-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center